Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 9/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16998541 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNAMEN1NPC1GALR3 | |
| SCHEMBL16998539 | 0.92 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNAMEN1NPC1GALR3 | |
| SCHEMBL16998550 | 0.91 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAMEN1NPC1GALR3 | |
| SCHEMBL16998543 | 0.91 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAMEN1NPC1GALR3 | |
| SCHEMBL16998542 | 0.91 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAMEN1NPC1GALR3 | |
| SCHEMBL15566227 | 0.91 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAMEN1NPC1GALR3 | |
| SCHEMBL25955362 | 0.90 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAMEN1NPC1GALR3 | |
| SCHEMBL18649663 | 0.90 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAMEN1NPC1GALR3 | |
| SCHEMBL26848566 | 0.90 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAMEN1NPC1GALR3 | |
| SCHEMBL15596698 | 0.88 | APP (0.48) | SMN1; SMN2LMNAMEN1NPC1GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3058960-B1 | DIAGNOSTIC AGENT FOR THERAPEUTIC EFFECT ON CANCER | HAMAMATSU PHOTONICS KK (JP) | 2023-08-30 | — | — | EP | disclosed |
| US-9872928-B2 | Diagnostic agent for therapeutic effect on cancer | HAMAMATSU PHOTONICS K.K. (JP) | 2018-01-23 | — | — | US | disclosed |
| US-9872928-B2 | Diagnostic agent for therapeutic effect on cancer | HAMAMATSU PHOTONICS K.K. (JP) | 2018-01-23 | — | — | US | disclosed |
| US-9598399-B2 | Compound suitable for detection of mitochondrial complex-1 | HAMAMATSU PHOTONICS K.K. (JP) | 2017-03-21 | — | — | US | disclosed |
| US-9598399-B2 | Compound suitable for detection of mitochondrial complex-1 | HAMAMATSU PHOTONICS K.K. (JP) | 2017-03-21 | — | — | US | disclosed |
| US-20160256578-A1 | DIAGNOSTIC AGENT FOR THERAPEUTIC EFFECT ON CANCER | HAMAMATSU PHOTONICS K.K. (JP) | 2016-09-08 | — | — | US | disclosed |
| US-20160256578-A1 | DIAGNOSTIC AGENT FOR THERAPEUTIC EFFECT ON CANCER | HAMAMATSU PHOTONICS K.K. (JP) | 2016-09-08 | — | — | US | disclosed |
| US-20150225368-A1 | COMPOUND SUITABLE FOR DETECTION OF MITOCHONDRIAL COMPLEX-1 | HAMAMATSU PHOTONICS K.K. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225368-A1 | COMPOUND SUITABLE FOR DETECTION OF MITOCHONDRIAL COMPLEX-1 | HAMAMATSU PHOTONICS K.K. (JP) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256578-A1 | DIAGNOSTIC AGENT FOR THERAPEUTIC EFFECT ON CANCER | NOC2L, NOP56, NPM1 | SMN1; SMN2 1322/4885LMNA 2038/4885MEN1 236/4885 |
| US-20150225368-A1 | COMPOUND SUITABLE FOR DETECTION OF MITOCHONDRIAL COMPLEX-1 | MT-ND1, MT-CO1, UQCRC1 | SMN1; SMN2 1449/4885LMNA 2024/4885MEN1 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.